<code id='20B5480127'></code><style id='20B5480127'></style>
    • <acronym id='20B5480127'></acronym>
      <center id='20B5480127'><center id='20B5480127'><tfoot id='20B5480127'></tfoot></center><abbr id='20B5480127'><dir id='20B5480127'><tfoot id='20B5480127'></tfoot><noframes id='20B5480127'>

    • <optgroup id='20B5480127'><strike id='20B5480127'><sup id='20B5480127'></sup></strike><code id='20B5480127'></code></optgroup>
        1. <b id='20B5480127'><label id='20B5480127'><select id='20B5480127'><dt id='20B5480127'><span id='20B5480127'></span></dt></select></label></b><u id='20B5480127'></u>
          <i id='20B5480127'><strike id='20B5480127'><tt id='20B5480127'><pre id='20B5480127'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:8621
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          FDA panel to weigh approval of NurOwn, controversial ALS drug
          FDA panel to weigh approval of NurOwn, controversial ALS drug

          AdobeYearsofpolarizingscientificdiscourseandbruisingonlinedebatewillcometoaheadnextweekwhenadviserst

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          It's been 20 years since Dolly the sheep. Where's my clone?

          AlexHogan/STAT,GettyImagesDolly,thefirstanimaltobeclonedfromanadultofitsspecies,wasborn20yearsagotod